Iantrek Expands Clinical Evidence for Bio-Interventional Ophthalmic Surgery Across Trabecular and Uveoscleral Outflow Pathways
Iantrek, Inc., a company pioneering bio-interventional ophthalmic surgery (BIOS), today announced topline six-month results from a first-in-human, investigator-initiated study evaluating bio-reinforced canaloplasty targeting the trabecular outflow pathway. At six months, mean intraocular pressure (IOP) decreased by 37.2% from a baseline of 22.4 mmHg, with 90% of eyes achieving an IOP of 18 mmHg or lower. Mean glaucoma medication use also decreased by 49.1% from a baseline of 1.2 medications.